INDIANAPOLIS, Nov. 16,
2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:
LLY) will attend the fifth annual Evercore ISI HealthCONx
Conference on Wednesday, Nov. 30,
2022. Jacob Van Naarden, Lilly executive vice president and
CEO of Loxo@Lilly, and David Hyman,
M.D., chief medical officer, Loxo@Lilly, will participate in a
fireside chat at 12:10 p.m., Eastern
time.
A live audio webcast will be available on the "Webcasts &
Presentations" section of Lilly's Investor website at
https://investor.lilly.com/webcasts-and-presentations. A replay of
the presentation will be available on this same website for
approximately 90 days.
About Lilly
Lilly unites caring with discovery to create medicines that make
life better for people around the world. We've been pioneering
life-changing discoveries for nearly 150 years, and today our
medicines help more than 47 million people across the globe.
Harnessing the power of biotechnology, chemistry and genetic
medicine, our scientists are urgently advancing new discoveries to
solve some of the world's most significant health challenges,
redefining diabetes care, treating obesity and curtailing its most
devastating long-term effects, advancing the fight against
Alzheimer's disease, providing solutions to some of the most
debilitating immune system disorders, and transforming the most
difficult-to-treat cancers into manageable diseases. With each step
toward a healthier world, we're motivated by one thing: making life
better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more,
visit Lilly.com and Lilly.com/newsroom or
follow us on Facebook, Instagram, Twitter and LinkedIn.
F-LLY
Refer to:
|
Jordan Bishop;
jordan.bishop@lilly.com; 317-473-5712 (Media)
|
|
Joe Fletcher;
jfletcher@lilly.com; 317-296-2884 (Investors)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-to-participate-in-evercore-isi-healthconx-conference-301678641.html
SOURCE Eli Lilly and Company